The survival kinases Akt and Pim as potential pharmacological targets

被引：359
|
作者：
Amaravadi, R [1 ]
Thompson, CB [1 ]
机构：
[1] Univ Penn, Abramson Family Canc Res Inst, Dept Canc Biol & Med, Philadelphia, PA 19104 USA
来源：
JOURNAL OF CLINICAL INVESTIGATION | 2005年 / 115卷 / 10期
关键词：
D O I：
10.1172/JCI26273
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
The Akt and Pim kinases are cytoplasmic serine/threonine kinases that control programmed cell death by phosphorylating substrates that regulate both apoptosis and cellular metabolism. The PI3K-dependent activation of the Akt kinases and the JAK/STAT-dependent induction of the Pim kinases are examples of partially overlapping survival kinase pathways. Pharmacological manipulation of such kinases could have a major impact on the treatment of a wide variety of human diseases including cancer, inflammatory disorders, and ischemic diseases.
引用
收藏
页码：2618 / 2624
页数：7
相关论文
共 50 条
  • [21] Pim-1 regulates cardiomyocyte survival downstream of Akt
    Muraski, John A.
    Fransioli, Jenna
    Gude, Natalie
    Martindale, Joshua
    Glembotski, Christopher
    Magnuson, Nancy
    Berns, Anton
    Sussman, Mark A.
    CIRCULATION, 2006, 114 (18) : 294 - 294
  • [22] PIM kinases regulates tumor associated macrophage survival and inflammatory signaling
    Clements, Amber N.
    Warfel, Noel A.
    CANCER RESEARCH, 2023, 83 (11)
  • [23] PIM kinases to the rescue
    Lucy Bird
    Nature Reviews Immunology, 2005, 5 : 187 - 187
  • [24] Targeting PIM kinases in cancer therapy: An update on pharmacological small-molecule inhibitors
    Chen, Siwei
    Yang, Yushang
    Yuan, Yong
    Liu, Bo
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 264
  • [25] Potential Pharmacological Inhibitors of Pim Kinase Under Clinical Trials
    Jeyapal, Gomathi P.
    Chandrasekar, Moola J. N.
    Krishnasamy, Rajendiran
    Selvaraj, Jubie
    Mohammad, Manal
    Nanjan, Moola J.
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2018, 18 (08) : 1100 - 1114
  • [26] Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival
    Hammerman, PS
    Fox, CJ
    Birnbaum, MJ
    Thompson, CB
    BLOOD, 2005, 105 (11) : 4477 - 4483
  • [27] The PIM family of oncoproteins: small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets
    Saurabh, Kumar
    Scherzer, Michael T.
    Shah, Parag P.
    Mims, Alice S.
    Lockwood, William W.
    Kraft, Andrew S.
    Beverly, Levi J.
    ONCOTARGET, 2014, 5 (18) : 8503 - 8514
  • [28] The Pim kinases control rapamycin-resistant T cell survival and activation
    Fox, CJ
    Hammerman, PS
    Thompson, CB
    JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 201 (02): : 259 - 266
  • [29] Cell-permeable dual inhibitors of protein kinases CK2 and PIM-1: structural features and pharmacological potential
    Cozza, Giorgio
    Girardi, Cristina
    Ranchio, Alessandro
    Lolli, Graziano
    Sarno, Stefania
    Orzeszko, Andrzej
    Kazimierczuk, Zygmunt
    Battistutta, Roberto
    Ruzzene, Maria
    Pinna, Lorenzo A.
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2014, 71 (16) : 3173 - 3185
  • [30] Expression of Akt/Pim-1 Survival Proteins in Myocardial Remodeling
    Gao, Yang
    Savai, Kinjal
    Li, Tielou
    Wu, Changfu
    Bond, Meredith
    Wu, Zhongjun J.
    Griffith, Bartley P.
    CIRCULATION RESEARCH, 2008, 103 (05) : E47 - E47
12345